Why the study?
Inflammation plays a pivotal role in the pathophysiology of AMI, warranting a systematic review of anti-inflammatory trials, their designs, efficacies, challenges, and translational implications.
Do anti-inflammatory interventions improve outcomes in patients with acute myocardial infarction?
Do anti-inflammatory interventions improve outcomes in patients with acute myocardial infarction?
This comprehensive review highlights the evolving landscape, efficacies, and challenges of targeting inflammation in patients following acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Anti-inflammatory strategies post-AMI remain investigational; leaves open clinical efficacy while extending synthesis of trial designs and translational barriers.
The role of inflammation in the pathophysiology of acute myocardial infarction (AMI) is well established. In recognizing inflammation's pivotal role in AMI, this manuscript systematically traces the historical studies spanning from early attempts to the present landscape. Several anti-inflammatory trials targeting inflammation in post-AMI have been performed, and this review includes the key trials, as well as examines their designs, patient demographics, and primary outcomes. Efficacies and challenges are analyzed, thereby shedding light on the translational implications of trial outcomes. This article also discusses emerging trends, ongoing research, and potential future directions in the field. Practical applications and implications for clinical practice are considered by providing a holistic view of the evolving landscape of anti-inflammatory interventions in the context of AMI.
No takes yet. Share an insight, caveat, or question.
Mitsis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: